Dopamine Transporter

Attention deficit/hyperactivity disorder (ADHD) affects between 3% and 5% of schoolage children. Treatment of major symptoms, such as inattention, hyperactivity, and impulsive behavior, has been effectively achieved using psychostimulants, of which methylphenidate (RitalinĀ®) is the most commonly prescribed in the United States. These drugs are beneficial in many cases; however, inter-individual variation in clinical response and adverse events is well documented (55-57). Methylphenidate binds to and directly inhibits the dopamine transporter (DAT1). Accordingly, variations in genes involved in dopamine action and metabolism (such as DAT1, D2, and the D4 receptor genes) have been examined in search for explanation of the variability in clinical response to methylphenidate and other psychostimulants in ADHD patients. A recent study (58) demonstrated significant association between the 10/10 genotype in DAT1 and lack of response to methylphenidate but failed to demonstrate any association with polymorphism in the dopamine receptors (58). These results have recently been confirmed in a larger patient cohort (59).

Understanding And Treating ADHD

Understanding And Treating ADHD

Attention Deficit Disorder or ADD is a very complicated, and time and again misinterpreted, disorder. Its beginning is physiological, but it can have a multitude of consequences that come alongside with it. That apart, what is the differentiation between ADHD and ADD ADHD is the abbreviated form of Attention Deficit Hyperactive Disorder, its major indications being noticeable hyperactivity and impulsivity.

Get My Free Ebook

Post a comment